Ursodiol is a foundational therapeutic agent used across key domains of liver and biliary health. Its therapeutic application provides support that helps ease the overall symptom burden for patients facing chronic conditions or the risk of gallstone formation.

The primary therapeutic areas involve supportive care for Primary Biliary Cholangitis (PBC), is relevant for easing symptoms associated with small, cholesterol-based gallstones, and is applied across domains like Intrahepatic Cholestasis of Pregnancy (ICP) and issues related to Cystic Fibrosis. This medication is generally used for the long-term management of chronic conditions, particularly PBC, where it may assist with maintaining functional stability.

Supportive Care and Symptom Relief

For patients with gallstones, this therapy contributes to easing symptoms related to physical discomfort that may intensify over time. In specialized cases, it is commonly used to help with symptoms that interfere with daily comfort, such as intense itching.

“The overall intent is to help patients cope more steadily with symptom fluctuations and support general well-being during symptomatic phases.”

---

Quick Fact: Symptomatic Assistance for Pruritus

Property	Description
Primary Indication Focus	PBC, Cholesterol Gallstone Disease
Key Symptom Addressed	Severe, debilitating pruritus (itching) associated with cholestasis
General Benefit	Contributes to improved comfort and supports functional stability

Regulatory References

1. NIH MedlinePlus Drug Information overview

Eligibility Map: Who Can and Cannot Use Ursodiol

Official regulatory guidelines define specific patient populations for whom the use of Ursodiol is established, restricted, or strictly prohibited.

Contraindications (Must Not Use)

Use of Ursodiol is formally contraindicated in patients with a known hypersensitivity to the medicine or bile acids. It must also not be used if the biliary tract is completely blocked (biliary obstruction), if the gallbladder is non-functional, or if there is acute inflammation of the gallbladder or bile ducts. Additionally, the medicine is ineffective and contraindicated for patients with radio-opaque calcified gallstones or those experiencing repeated episodes of biliary colic.

Age and Reproductive Status

Population	Regulatory Status
Adults	Established use for primary indications.
Pediatric Use (US)	Safety and efficacy have not been established for US-approved indications.
Pediatric Use (EU/UK)	Approved for specific hepatobiliary disorders associated with cystic fibrosis (ages 6–18).
Pregnancy	Contraindicated in the first trimester; generally not recommended throughout pregnancy.
Lactation	Not recommended; caution is required, and some labeling suggests discontinuing breastfeeding.

Condition-Specific Limitations

Eligibility is restricted for women of childbearing potential, who must use reliable non-hormonal contraception during treatment. Caution is required in patients with advanced chronic liver disease or conditions that interfere with the natural entero-hepatic circulation of bile salts.

Interactions with other medicines and products

The official interaction profile for Ursodiol (Ursodeoxycholic Acid) is classified based on two main categories: physical binding interactions and pharmacodynamic/exposure alterations, as defined in regulatory documents.

---

Timing-Separation Interactions

Substances that physically bind bile acids in the gastrointestinal tract can reduce the absorption and effectiveness of Ursodiol. This applies to bile acid sequestering agents (such as Cholestyramine) and aluminum-based antacids. To prevent this interference, these binding agents, including Charcoal, must be taken with a mandatory two-hour separation before or after Ursodiol administration.

---

Pharmacodynamic and Exposure Alterations

Certain hormonal and lipid-lowering medicines may counteract Ursodiol's primary function. Estrogens, Oral Contraceptives, and Clofibrate may increase cholesterol secretion in the bile, thereby diminishing the intended effect of Ursodiol.

Additionally, Ursodiol can alter the systemic exposure of co-administered drugs. This profile includes an increased absorption of Cyclosporine, which may necessitate monitoring of its blood levels. Conversely, Ursodiol may cause a reduction in plasma concentrations for medicines like Nitrendipine and has been reported to reduce the therapeutic effect of Dapsone and Ciprofloxacin. Controlled clinical trials have also determined that Ursodiol does not have a relevant inductive effect on cytochrome P450 3A enzymes.

How Ursodiol Works

Ursodiol (Ursodeoxycholic Acid, UDCA) is a highly hydrophilic bile acid that exerts its physiological effects across three primary mechanistic domains within the enterohepatic system.

UDCA modifies biliary cholesterol saturation by two interactions: it suppresses the synthesis and secretion of cholesterol from the liver and inhibits its intestinal absorption. This dual action reduces the cholesterol concentration in bile, promoting the dispersion of cholesterol as liquid crystals rather than solid precipitates, thereby leading to a physiological state of reduced biliary cholesterol saturation.

Simultaneously, UDCA achieves cytoprotection through competitive displacement of more toxic hydrophobic bile acids from the circulating pool. It directly stabilizes the membranes of hepatocytes and cholangiocytes and inhibits pro-apoptotic pathways. This results in the maintenance of cellular structural integrity and decreased chemically-induced cellular stress within the liver. UDCA also acts as a choleretic agent by modulating the chloride-bicarbonate anion exchanger (AE2), stimulating the secretion of water and electrolytes, which results in an increased volume of aqueous bile secretion and enhanced mass transfer through the bile ducts.

Ursodiol is administered solely through the oral route, primarily available as capsules, tablets, and oral suspension. All forms should be taken with food or liquid to facilitate proper absorption. For patients whose dose requires precise measurement, the 500 mg scored tablets can be broken in half, but the resulting segments must not be chewed.

The required dosage is weight-based, with the specific daily amount calculated in milligrams per kilogram of body weight. Standard regimens differ based on the use context: 13 to 15 mg/kg/day is the typical range for Primary Biliary Cholangitis (PBC), while 8 to 12 mg/kg/day is used for cholesterol gallstone dissolution. The total daily dose is typically divided and taken in two to four administrations. For gallstone dissolution, administration is often consolidated so that the largest or entire dose is taken once daily in the evening before bedtime.

Treatment for PBC is defined as long-term management, while gallstone dissolution therapy typically runs for six months up to two years and must be continued for several months after dissolution is confirmed. Dosing for specific populations, such as children with Cystic Fibrosis-associated liver disease, follows a distinct weight-based regimen. If a dose is missed, it is generally recommended that it be skipped if the next dose time is near; a double dose must not be taken to compensate. The prescribed dose may also be temporarily reduced if gastrointestinal symptoms, such as diarrhea, become prominent.

Research Evidence / Overview of Studies for Ursodiol

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research examined Ursodiol in Primary Biliary Cholangitis (PBC) and has included numerous controlled trials and long-term observational studies. Researchers monitored outcomes related to systemic or functional imbalance, such as changes in liver biochemistry markers like alkaline phosphatase (ALP) and bilirubin, as well as critical events, including the need for liver transplantation.

The findings describe patterns observed in the studies where lower measurements of serum alkaline phosphatase were reported for participants in the Ursodiol cohorts compared to those in control groups. Some long-term research indicates patterns regarding the progression of the condition. However, findings were mixed when studies examined patient-reported outcomes describing perceived discomfort, particularly for symptoms like fatigue.

Evidence for Gallstone Dissolution and Prevention

Ursodiol was studied for two separate scenarios: achieving dissolution of existing stones and preventing new stones from forming. For dissolution, controlled trials were evaluated in patients who had small to moderate-sized, non-calcified gallstones. Research explored the rate at which complete or partial stone dissolution was observed on imaging.

Studies report how dissolution evolved in the observed populations, with data showing patterns related to higher rates of dissolution reported in studies involving smaller gallstones. For prevention, research described patterns where the incidence of new stone formation was reported less frequently in the Ursodiol cohort compared to the placebo cohort in short-term studies.

What is Still Uncertain About Ursodiol Research

Ursodiol was evaluated in various study populations. Research examined outcomes for children (the pediatric population) and some studies included older adults, but the study results apply only to the populations studied in those smaller cohorts. Data for certain groups remain insufficient, and limited information for long-term outcomes is available for these special populations specifically.

Certainty remains low in some areas. Findings were mixed regarding subjective patient experiences, indicating that more focused research is ongoing. Comparative evidence is lacking in some areas, such as robust data comparing Ursodiol against newer therapeutic options for PBC. Overall, evidence highlights what is known—and what is still uncertain. The available research does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References

1. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis
2. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (AASLD)

Common questions about Ursodiol (FAQ)

---

Q: What should I do if I miss a dose of Ursodiol?

The official instructions indicate that a missed dose may be taken as soon as you remember. However, if it is close to the time for the next scheduled dose, regulatory guidance suggests skipping the missed dose and continuing with the regular schedule. Official instructions specify that a double dose must not be taken to compensate for a missed dose.

---

Q: Can I split the tablets?

The official product information confirms that the scored Ursodiol tablets can be broken in half. The purpose of the scoring is to facilitate precise dose measurement when required. The resulting segments from a split tablet must not be chewed, as specified in the product label. Any unused half-tablet should be stored correctly and used within 28 days.

---

Q: What is the name of the generic form of Ursodiol?

The name of the active ingredient, which serves as the generic name for the medication, is ursodeoxycholic acid (UDCA). This is the standard chemical designation used in regulatory documents worldwide.

---

Q: Does Ursodiol make you gain weight?

Weight changes are not listed as a common side effect in initial regulatory documents. However, postmarketing experience includes reports of unusual weight gain or loss, as well as peripheral edema (swelling, often in the legs or hands). Any concerns about rapid or unexplained weight changes should be discussed with a healthcare provider.

---

Q: What foods should I avoid while taking Ursodiol?

Regulatory documents do not strictly prohibit specific foods while taking Ursodiol. However, since the medicine works to alter bile composition, some official guidance suggests trying to avoid foods that are very high in cholesterol and calories. Specific dietary recommendations are typically provided by the prescribing healthcare provider.

---

Q: Can I drive after taking this medicine?

According to official product information, there are no known effects of Ursodiol on a person’s ability to drive or operate machines. Although dizziness is listed as a potential side effect, official labeling does not include a specific general warning against driving or operating machinery.

---

Q: Is it better to take Ursodiol in the morning or at night?

The required total daily dose of Ursodiol is usually divided and taken with food throughout the day. For patients being treated for gallstone dissolution, the largest or entire dose is often recommended to be taken once daily in the evening at bedtime. Some patients being treated for Primary Biliary Cholangitis (PBC) may also shift to taking the full daily dose once at night after the initial treatment period.

Storage and Disposal of Ursodiol

Ursodiol (ursodeoxycholic acid) must be stored at Controlled Room Temperature, ideally between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container with the lid tightly closed and protected from moisture to maintain product stability. To ensure safety, Ursodiol must be stored out of the sight and reach of children.

Disposal instructions mandate that unused or expired medicine must not be flushed down a toilet or poured down a drain. Instead, the product should be mixed with an undesirable substance, sealed in a bag, and then discarded with household trash.